BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 25137174)

  • 1. [Intralesional rituximab in ocular adnexal lymphoma].
    Crespo Robledo P; Vázquez Castillo MJ
    Farm Hosp; 2014 Jul; 38(4):386-7. PubMed ID: 25137174
    [No Abstract]   [Full Text] [Related]  

  • 2. Intralesional rituximab in primary conjunctival follicular lymphoma relapsed.
    Rodríguez Villa S; Ruiz Rodríguez MJ; Vargas Pabón M
    Arch Soc Esp Oftalmol; 2017 Jul; 92(7):326-329. PubMed ID: 27986437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intralesional Rituximab for the Treatment of Recurrent Ocular Adnexal Lymphoma.
    Demirci H; Kauh CY; Rajaii F; Elner VM
    Ophthalmic Plast Reconstr Surg; 2017; 33(3S Suppl 1):S70-S71. PubMed ID: 26950471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local treatment for lymphoid malignancies of the eye.
    Giuliari GP; Hinkle DM; Foster CS
    Anticancer Agents Med Chem; 2009 Dec; 9(10):1123-8. PubMed ID: 19925396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcomes of primary ocular adnexal lymphoma treatment with intraorbital rituximab injections.
    Savino G; Battendieri R; Gari M; Caputo CG; Laurenti L; Blasi MA
    J Cancer Res Clin Oncol; 2013 Jul; 139(7):1251-5. PubMed ID: 23625184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Intravitreal rituximab for the treatment of intraocular relapse of non-Hodgkin's lymphoma].
    Fernández Cañabate E; Fernández-Cañabate S
    Farm Hosp; 2018 Jan; 42(1):20-21. PubMed ID: 29306309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas.
    Ferreri AJ; Govi S; Colucci A; Crocchiolo R; Modorati G
    Ophthalmology; 2011 Jan; 118(1):24-8. PubMed ID: 20709407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intralesional Rituximab Treatment for Primary Cutaneous B-cell Lymphoma: Nine Finnish Cases.
    Väkevä L; Ranki A; Mälkönen T
    Acta Derm Venereol; 2016 Mar; 96(3):396-7. PubMed ID: 26525093
    [No Abstract]   [Full Text] [Related]  

  • 9. Rituximab and chlorambucil as first-line treatment for low-grade ocular adnexal lymphomas.
    Rigacci L; Nassi L; Puccioni M; Mappa S; Polito E; Dal Pozzo S; Alterini R; Carrai V; Puccini B; Bosi A
    Ann Hematol; 2007 Aug; 86(8):565-8. PubMed ID: 17483948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intralesional Rituximab Injection for Low-Grade Conjunctival Lymphoma Management.
    Demirci H; Ozgonul C; Diniz Grisolia AB; Elner VM
    Ophthalmology; 2020 Sep; 127(9):1270-1273. PubMed ID: 32336490
    [No Abstract]   [Full Text] [Related]  

  • 11. Conjunctival and orbital lymphoma.
    Shinder R
    Ophthalmology; 2011 Aug; 118(8):1692; author reply 1692, 1692.e1. PubMed ID: 21813098
    [No Abstract]   [Full Text] [Related]  

  • 12. Follicular lymphoma of the ocular adnexal region: a nation-based study.
    Rasmussen PK; Ralfkiaer E; Prause JU; Sjö LD; Specht L; Rossing HH; Siersma VD; Heegaard S
    Acta Ophthalmol; 2015 Mar; 93(2):184-91. PubMed ID: 25125069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous rituximab and chemotherapy achieves similar overall response rates to intravenous rituximab in first-line follicular lymphoma: efficacy and safety results of the phase III SABRINA study.
    Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):6-7. PubMed ID: 25768992
    [No Abstract]   [Full Text] [Related]  

  • 14. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
    Rasmussen PK
    Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monthly administration of rituximab is useful for patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma.
    Mino T; Mihara K; Yoshida T; Takihara Y; Ichinohe T
    Blood Cancer J; 2014 Sep; 4(9):e245. PubMed ID: 25215661
    [No Abstract]   [Full Text] [Related]  

  • 16. Intraocular use of rituximab.
    Kitzmann AS; Pulido JS; Mohney BG; Baratz KH; Grube T; Marler RJ; Donaldson MJ; O'Neill BP; Johnston PB; Johnson KM; Dixon LE; Salomao DR; Cameron JD
    Eye (Lond); 2007 Dec; 21(12):1524-7. PubMed ID: 17464308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged remission in a patient with relapsed follicular lymphoma after a single course of rituximab.
    Jensen M; Elter T; Engert A; Reiser M
    Onkologie; 2006 Mar; 29(3):90-2. PubMed ID: 16514269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late occurrence of Epstein-Barr virus-associated lymphoproliferative disorder in a patient with follicular lymphoma treated with bendamustine and rituximab.
    Muroi K; Sakata-Yanagimoto M; Sato T; Yokoyama Y; Maie K; Kurita N; Obara N; Hasegawa Y; Noguchi M; Chiba S
    Ann Hematol; 2015 Dec; 94(12):2061-2. PubMed ID: 26240012
    [No Abstract]   [Full Text] [Related]  

  • 19. Intra-CSF rituximab for lymhomatous meningitis.
    Chamberlain MC; Glantz MJ
    J Clin Oncol; 2007 Oct; 25(28):4508-9; author reply 4509-11. PubMed ID: 17906219
    [No Abstract]   [Full Text] [Related]  

  • 20. Intraocular rituximab.
    Singh AD; Peereboom DM
    Eye (Lond); 2007 Dec; 21(12):1453-4. PubMed ID: 18159211
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.